Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, $0.001 par value per share · CUSIP: 05338F306
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.
Shares: 1,939,065.00 · Class: 9.9%
- Peter Kolchinsky
Shares: 1,939,065.00 · Class: 9.9%
- Rajeev Shah
Shares: 1,939,065.00 · Class: 9.9%
- RA Capital Healthcare Fund, L.P.
Shares: 1,939,065.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-26-000035
- Form type
- SCHEDULE 13G/A
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership